AR and prostate carcinoma: Takeda and coworkers have reanalyzed previously published data from castration-resistant prostate cancers and identified repeated DNA sequences acting as enhancers that caused the abnormal amplification of the region upstream AR: duplication of this enhancer region improved the tumorigenic process and increased androgen resistance, while its targeting by gene editing de creased AR expression and tumor cell proliferation [163].